All In MedTech

Device Trial Radar · NCT07675395

Atrial Remodeling After PFA Substrate Modification for Persistent AF (PeAF)

Pulsed-Field Ablation for Persistent Atrial Fibrillation: Impact of Atrial Remodeling After Substrate Modification

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitation

Status

Enrolling by invitation

Enrollment

30

Planned (sponsor's estimate)

Start

Jul 1, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Boston Scientific Corporation
First posted
Jun 30, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atrial fibrillation (AF) is associated with both electrical and structural remodeling of the left atrium. While successful catheter ablation has been shown to reverse some aspects of atrial remodeling, the impact of pulsed-field ablation (PFA) - a non-thermal ablation technology that selectively targets cardiomyocytes while sparing surrounding structures - on atrial remodeling in patients with persistent AF undergoing extensive substrate modification remains unclear. This is a prospective, single-center, single-arm observational study conducted at Taipei Veterans General Hospital. The study will enroll 30 patients with persistent atrial fibrillation who undergo pulmonary vein isolation (PVI) and extensive substrate modification using the FARAWAVE / FARADRIVE Catheter and FARASTAR System. The primary objective is to evaluate left atrial structural remodeling following PFA, including changes in LA size, atrial strain, extent of atrial fibrosis, and atrial hemodynamic function. The secondary objective is to assess AF-free survival between 3 and 12 months after the procedure, and its relationship to atrial remodeling. All participants will be followed for 12 months, with an interim analysis conducted once all subjects complete their 6-month follow-up.

Conditions

  • Persistent Atrial Fibrillation
  • Atrial Fibrillation (AF)
  • Atrial Remodeling
  • Pulsed Field Ablation

Interventions

  • Pulsed-Field Ablation with FARAWAVE Catheter SystemDevice

    Pulsed-field ablation is performed using the FARAWAVE / FARADRIVE Catheter and FARASTAR System (Boston Scientific) under deep sedation or general anesthesia. PFA is delivered to achieve pulmonary vein isolation and posterior wall isolation, with additional substrate modification at the operator's discretion. Invasive hemodynamic assessment is performed pre- and post-PFA during the index procedure and repeated at approximately 3 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Left Atrial Anteroposterior DiameterTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure
  2. Change in Left Atrial Volume IndexTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure
  3. Change in Left Atrial Reservoir StrainTime frame: Baseline, 3 months, 6 months, and 12 months post-procedure

8 more outcomes with a free account

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.